Effective June 9, 2021, the Company’s Board of Directors (the "Board") and its stockholders as of that date adopted and approved the LifeStance Health Group, Inc. 2021 Equity Incentive Plan (the “2021 Equity Incentive Plan”). The 2021 Equity Incentive Plan permits the grant of awards or restricted or unrestricted common stock, stock options, stock appreciation rights, restricted stock units, performance awards, and other stock-based awards to employees and directors of, and consultants and advisors to, the Company and its affiliates. On January 1, 2026, the number of shares of common stock reserved and available for issuance under the 2021 Equity Incentive Plan increased by 19,416 shares.

The following is a summary of RSA transactions as of and for the six months ended June 30, 2026:


	Unvested Shares			Weighted-Average Grant Date Fair Value
Unvested, December 31, 2025		1,268		$	11.98
Vested		—			11.98
Forfeited		(819	)		11.98
Unvested, June 30, 2026		449		$	11.98

The following is a summary of RSU transactions as of and for the six months ended June 30, 2026:


	Unvested Shares			Weighted-Average Grant Date Fair Value
Outstanding, December 31, 2025		25,852		$	7.02
Granted		5,557			7.04
Vested		(6,818	)		7.07
Canceled and forfeited		(5,915	)		6.72
Outstanding, June 30, 2026		18,676		$	7.11

The following is a summary of stock option activity as of and for the six months ended June 30, 2026:


	Number of Options			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding, December 31, 2025		13,476		$	7.42		5.43	$	1,888
Granted		—			—
Exercised		(705	)		7.61				2,187
Canceled and forfeited		(2,116	)		7.61
Outstanding, June 30, 2026		10,655		$	7.37		6.22	$	35,629
Exercisable at June 30, 2026		2,664		$	7.37		6.22	$	8,907
Vested or expected to vest at June 30, 2026		10,655		$	7.37		6.22	$	35,629

The Company recognized stock-based compensation expense related to RSUs and stock options within general and administrative expenses in the unaudited consolidated statements of operations and comprehensive income (loss) as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Stock-based compensation expense	$	19,748	$	21,116	$	34,949	$	39,700

As of June 30, 2026, the Company had $108,484 in unrecognized compensation expense related to all non-vested RSUs and stock options that will be recognized over the weighted-average remaining service period of 2.2 years.

Effective June 9, 2021, the Board and its stockholders as of that date adopted and approved the LifeStance Health Group, Inc. 2021 Employee Stock Purchase Plan (the “ESPP”). The ESPP is more fully described in Note 10 in the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

As of June 30, 2026, no shares of common stock have been purchased under the Company’s ESPP.

On February 24, 2026, the Company’s Board of Directors approved a share repurchase program (“Repurchase Program”), which authorizes the Company to repurchase up to $100,000 of the Company’s outstanding shares of common stock. The Repurchase Program does not obligate the Company to repurchase any particular amount of common stock. Stock repurchases under this program may be made at such times, prices, amounts and on such terms as the Company may determine from time to time to be advisable based on a variety of factors such as the market price of the Company’s common stock, the Company’s corporate requirements, other investment opportunities, and the overall market condition, with such repurchases effectuated in the open market or through privately

negotiated transactions (including accelerated share repurchase programs), block purchases, or exchange or non-exchange transactions, and using such broker-dealer or broker-dealers as the Company may determine. The Board of Directors may suspend, modify or terminate the Repurchase Program at any time without prior notice. The Company repurchased 6,000 and 13,000 shares of its common stock for $48,518 and $97,625 during the three and six months ended June 30, 2026, respectively.